124 related articles for article (PubMed ID: 38899786)
21. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis.
Frin AC; Filippi J; Boschetti G; Flourie B; Drai J; Ferrari P; Hebuterne X; Nancey S
Dig Liver Dis; 2017 Jan; 49(1):11-16. PubMed ID: 27693318
[TBL] [Abstract][Full Text] [Related]
22. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
Reinisch W; Bressler B; Curtis R; Parikh A; Yang H; Rosario M; Røseth A; Danese S; Feagan B; Sands BE; Ginsburg P; Dassopoulos T; Lewis J; Xu J; Wyant T
Inflamm Bowel Dis; 2019 Mar; 25(4):803-810. PubMed ID: 30295811
[TBL] [Abstract][Full Text] [Related]
23. Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission.
Kawashima K; Oshima N; Kishimoto K; Kataoka M; Fukunaga M; Kotani S; Sonoyama H; Oka A; Mishima Y; Kazumori H; Ishikawa N; Araki A; Ishihara S
Inflamm Bowel Dis; 2023 Mar; 29(3):359-366. PubMed ID: 35583193
[TBL] [Abstract][Full Text] [Related]
24. Cannabis for the treatment of ulcerative colitis.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
[TBL] [Abstract][Full Text] [Related]
25. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
Sandborn WJ; Panés J; Zhang H; Yu D; Niezychowski W; Su C
Gastroenterology; 2016 Jan; 150(1):96-102. PubMed ID: 26376350
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous Measurements of Faecal Calprotectin and the Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Stratify Risk of Relapse.
Nakarai A; Hiraoka S; Takahashi S; Inaba T; Higashi R; Mizuno M; Takashima S; Inokuchi T; Sugihara Y; Takahara M; Harada K; Kato J; Okada H
J Crohns Colitis; 2018 Jan; 12(1):71-76. PubMed ID: 28961792
[TBL] [Abstract][Full Text] [Related]
27. Etrasimod 2 mg Once Daily as Treatment for Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials.
Gastroenterol Hepatol (N Y); 2022 Jul; 18(7 Suppl 2):10. PubMed ID: 36756653
[No Abstract] [Full Text] [Related]
28. Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis.
Hiraoka S; Inokuchi T; Nakarai A; Takashima S; Takei D; Sugihara Y; Takahara M; Harada K; Okada H; Kato J
Gut Liver; 2018 Mar; 12(2):142-148. PubMed ID: 28873508
[TBL] [Abstract][Full Text] [Related]
29. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
[TBL] [Abstract][Full Text] [Related]
30. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
[TBL] [Abstract][Full Text] [Related]
31. Fecal calprotectin is a useful biomarker for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis in ulcerative colitis patients: a prospective observation study.
Ueno N; Sugiyama Y; Kobayashi Y; Murakami Y; Iwama T; Sasaki T; Kunogi T; Takahashi K; Tanaka K; Ando K; Kashima S; Inaba Y; Moriichi K; Tanabe H; Taruishi M; Saitoh Y; Okumura T; Fujiya M
BMC Gastroenterol; 2021 Aug; 21(1):316. PubMed ID: 34362299
[TBL] [Abstract][Full Text] [Related]
32. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program.
Dubinsky MC; Magro F; Steinwurz F; Hudesman DP; Kinnucan JA; Ungaro RC; Neurath MF; Kulisek N; Paulissen J; Su C; Ponce de Leon D; Regueiro M
Inflamm Bowel Dis; 2023 Jan; 29(1):51-61. PubMed ID: 35380664
[TBL] [Abstract][Full Text] [Related]
33. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.
Buisson A; Mak WY; Andersen MJ; Lei D; Kahn SA; Pekow J; Cohen RD; Zmeter N; Pereira B; Rubin DT
J Crohns Colitis; 2019 Aug; 13(8):1012-1024. PubMed ID: 30726887
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease.
Swaminathan A; Borichevsky GM; Frampton CM; Day AS; Hampton MB; Kettle AJ; Gearry RB
Inflamm Bowel Dis; 2024 Feb; ():. PubMed ID: 38417068
[TBL] [Abstract][Full Text] [Related]
35. P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
Hudesman D; Long M; Wolf D; Hanauer S; Ghosh S; Petersen A; Pondel M; Silver M; Cross R; Feagan B
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461954
[TBL] [Abstract][Full Text] [Related]
36. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis.
Xiang JY; Ouyang Q; Li GD; Xiao NP
World J Gastroenterol; 2008 Jan; 14(1):53-7. PubMed ID: 18176961
[TBL] [Abstract][Full Text] [Related]
37. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
[TBL] [Abstract][Full Text] [Related]
38. Etrasimod: First Approval.
Shirley M
Drugs; 2024 Feb; 84(2):247-254. PubMed ID: 38388871
[TBL] [Abstract][Full Text] [Related]
39. Faecal calprotectin is a surrogate marker of biliary inflammation in primary sclerosing cholangitis associated inflammatory bowel disease.
Pavlidis P; Joshi D; El Sherif Y; Warner B; Gulati S; Alexander J; Cross G; Dew T; Arqoub HA; Devlin J; Heneghan M; Dubois P; Bjarnason I; Powell N; Hayee B
Frontline Gastroenterol; 2022; 13(6):497-502. PubMed ID: 36250171
[TBL] [Abstract][Full Text] [Related]
40. Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
Danese S; Neurath MF; Kopoń A; Zakko SF; Simmons TC; Fogel R; Siegel CA; Panaccione R; Zhan X; Usiskin K; Chitkara D
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2526-2534.e9. PubMed ID: 31926340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
